Recently, the US bio-pharmaceutical industry analyst George Budwell select the S & P 500 dividend aristocrats index (refer to the past 25 years the annual dividend in the growth of company performance) as a measure of the Abbvie, Johnson & Johnson and Medtronic three biomedical companies listed The three most worthwhile companies in the Trump era. As soon as the news came out, Johnson & Johnson's stock price soared again. We may wish to dig deep into the brilliant achievements of Johnson & Johnson in recent years and understand the mysteries. Johnson & Johnson pharmaceutical sales in the past two years have exceeded 70 billion US dollars In the top ten multinational pharmaceutical companies in 2016, Johnson & Johnson continued to rank first with sales of US$71.89 billion. Among them, the pharmaceutical sector accounted for 43.72% of its total revenue with US$31.43 billion, sales increased by 6.5% year-on-year, and the medical device and consumer health sectors accounted for US$25.137 billion and US$13.507 billion, respectively. The sales revenue was 35.00% and 18.79%, and the sales volume decreased slightly. The United States is the main market for Johnson & Johnson, with a sales contribution rate of 52.60% and sales growth of 6% year-on-year, while sales in developed regions such as Europe and the Western Hemisphere declined in 2016. At the same time, sales in emerging markets such as Asia Pacific and Africa The amount has increased by 1.8%, and the contribution rate in 2016 is 17.49%. Immune system drugs accounted for 35.76% of the total sales revenue, and sales increased by 15.10% year-on-year. Cardiovascular/metabolic drugs ranked second with 19.11%, and sales of such drugs decreased slightly year-on-year. Cancer drugs increased by 23.70% year-on-year in 2016. 12 major products rose in 2016 Male Health,Health Powder,Epimedium Extract,Healthcare Supplements Shaanxi Changsheng Industrial Co., Ltd. , https://www.cncsbio.com
